Autres langues Vigil Neuroscience, Inc.

Actions

VIGL

US92673K1088

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 06/05/2024			Varia. 5j.	Varia. 1 janv.
2,89 ^USD	-4,62%		+11,15%	-14,50%

17/04	Vigil Neuroscience, Inc. présente les principaux résultats des études Illuminate et Ignite dans l'ALSP lors de la réunion annuelle de l'American Academy of Neurology en 2024	CI
26/03	VIGIL NEUROSCIENCE, INC. : Wedbush maintient sa recommandation à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting	17/04
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	17/04
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26/03
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
North American Morning Briefing : Markets Steady -2-	26/03
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer	20/03
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	20/03
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	20/03
Vigil Neuroscience, Inc. Announces Executive Changes	20/03
North American Morning Briefing : Stock Futures -2-	19/03
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	13/03
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	13/03
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days	12/03
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024	06/03
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	29/02
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	29/02
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference	07/02
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones	03/01
North American Morning Briefing : S&P 500 Futures -2-	20/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vigil Neuroscience, Inc.

Actions

VIGL

US92673K1088

Autres langues

Filtres